Special Offer

Stock Analysis Summary: CIPLA

CIPLA Technical and Fundamental Analysis

Date Open High Low LTP Close Volume Delivery Vol
2019-07-19 550.80 552.00 535.50 536.80 536.70 783,708 24%
2019-07-18 558.85 559.00 545.50 546.10 547.00 1,355,289 36%
2019-07-17 554.00 558.50 547.45 557.00 557.55 1,034,734 27%
2019-07-16 554.75 558.45 549.40 554.00 553.55 1,460,303 38%
2019-07-15 559.90 560.50 548.60 551.00 550.55 842,129 39%
2019-07-12 554.00 566.50 547.20 555.80 556.80 1,485,506 36%
2019-07-11 549.00 553.80 546.00 552.90 552.40 726,448 28%
*Markets are currently closed.

CIPLA breached the lows of past 8 days - 534 to act as intraday support.
CIPLA is trading below short term and medium term Moving Averages. Bearish

CIPLA is trading near the Bottom of the day's range. Lower High and Lower Low compared to previous day. Bearish
Day's Range: 535.50 ~ 552.00
CIPLA opened at 550.80 compared to previous close of 547.00

1 candlestick pattern: Similar to Black Marubozu. This is usually a bearish candle.
2 candlestick pattern: none
3 candlestick pattern: none

CIPLA day chart has unfilled gap up dated: 2019-04-05 526.00~522.00 to act as support.

Classic Pivot

S4 491.9
S3 508.4
S2 524.9
S1 530.8
LTP = 536.8
Pivot 541.4
R1 547.3
R2 557.9
R3 574.4
R4 590.9

Woodie's Pivot

S4 509.55
S3 526.05
S2 530.78
LTP = 536.8
S1 542.55
Pivot 547.28
R1 559.05
R2 563.78
R3 575.55
R4 592.05

Fibonacci Pivots

S3 524.9
S2 531.2
S1 535.1
LTP = 536.8
Pivot 541.4
R1 547.7
R2 551.6
R3 557.9

Camarilla Pivots

S4 527.63
S3 532.16
S2 533.68
S1 535.19
LTP = 536.8
R1 538.21
R2 539.73
R3 541.24
R4 545.78

*pivot points are calculated based on the closing data of 2019-07-19

Day's Range (.)

20 Day Range (.)

50 Day Range (.)

52-Week Range (.)

20-Day SMA: 550.7

20-Day average volume: 1,009,433

CIPLA has average daily volume of 1,009,433 compared to today's volume of 784,000. It is currently trading Below 20 day simple moving average.

Intraday Bearish!!!

50-Day SMA: 554.9
50-Day average volume: 1,724,044

Short Term Trend is Down!!!

It is currently trading about 21% below it's 52-week high.

Cipla Limited or CIPLA

The Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated in 1935. And Khwaja Abdul Hamied is the founder of Cipla who gave the company all of his patent & proprietary formulas for several drugs and medicines, without charging any particular royalty. As on August 17, 1935, Cipla was also registered as a pu..blic limited company with an authorized capital of INR 6 lakhs.

The business of the company :

It mainly focuses on the development of new formulations and also contains a wide range of pharmaceutical products and even offers prescription drugs, bulk drugs, animal products, and pesticides. It also deals in different types of food and beverages, baked foods, detergents, oral hygiene products, room fresheners, and personal care products, and much more. Approximately 55% of its overall income from its certain operations comes from overseas as it has 5,500 registered products in different countries. The Cipla offers drugs which are used for the treatment of cancer, Alzheimer's, arthritis, Parkinson, cardiovascular, and much more. It also provides medicines that prevent the transmission of AIDS from a mother to a child. It also offers various The Company offers consulting services on the preparation of products and materials, conducts plant evaluation, and supplies the plant equipment. It has set up the two institutes which are named as Dr. K. A Hamied Institute and the Cipla Cancer Palliative Care & Training Centre as well. It has its presence across 170 countries worldwide with various manufacturing units being approved by the regulatory authorities such as USFDA, WHO–Canada and MHRA–the UK, many others. The Cipla became the first company outside the US and Europe to launch the CFC or free inhalers. And in 2007, Cipla also launched an oral emergency contraceptive pill under the brand name as I–Pill and also launched a breakthrough screening technology in India. Also, the No-Touch Breast Scan or NTBS was the first ever painless, non–invasive, and radiation-free breast scanning technique for the detection of breast cancer at its initial stage. Then in 2009, it launched some of the generic versions of anti-flu drugs named oseltamivir and zanamivir in the local market to treat H1N1 influenza, which was spreading across the globe and especially in India. Later in 2010, the Piramal Healthcare Limited announced the signing of a definitive agreement with the Cipla Limited to purchase all the intellectual property rights in India related to 'i–pill' for an aggregate consideration of INR 95 crore.

Some of the Achievements:

  1. The company also won the "Forbes Asia's Best under a Billion" in the list from the Forbes Magazine.
  2. The Cipla also won the Most Profitable Company overall among its other competitors. Under a Billion in the Region and the Top 200 Small and Mid-Size companies from the Forbes Magazine.

The Milestones:

  1. 1998– It launched the lamivudine and became one of the few companies in the world to offer all three component drugs of the retroviral combination therapy in which zidovudine and stavudine were already launched.
  1. 1999– Launches Nevirapine, an antiretroviral drug, used to prevent the transmission of AIDS from mother to child.
  1. 2000– Cipla became the first company, outside the USA and Europe to launch CFC–free inhalers, that too ten years before the deadline to phase out the use of CFC in medicinal products.
  1. 2002– Four state–of–the–art manufacturing facilities set up in Goa in a record time of fewer than twelve months.
  1. 2003– Launches TIOVA (Tiotropium bromide), a novel inhaled, and a long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for all the patients with the chronic obstructive pulmonary disease (COPD). Commissioned the second phase of manufacturing operations at Goa.
  1. 2005– Sets–up state–of–the–art facility for the manufacture of formulations at Baddi, Himachal Pradesh.
  1. 2007– Sets–up state–of–the–art facility for the manufacture of formulations at Sikkim.
  1. 2010– Sets up state–of–the–art facility for production of formulations at Indore.

Disclaimer: This tool is designed for educational purpose only. Please consult your financial advisor before making any investing or trading decision. The site does not take any resposibility for any profit or loss.

What is Technical Stocks Analysis?

Technical Analysis is the study of …

NiftyTrader Technical Stocks Analysis is based on the following:

  1. Stock Momentum Study
  2. Stock Moving Averages
  3. Breakout and Breakdown based on Average Daily Volume
  4. Japanese Candlestick Pattern Recognition of high-potential candlestick patterns
  5. Pivot Analysis
  6. Intraday Sentiment among Traders and Investors
  7. 52-week high low summary

NiftyTrader Fundamental Stocks Analysis provide the following study of a particular stock:

  1. Balance Sheet – Comparison with previous years
  2. Quarterly and Annual Results Trend
  3. Cash Flow Analysis Trend
  4. Peer Comparison